Redox-inflammatory synergy in the metabolic syndrome

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 1, 2013, Pages 22-30

  Bryan, Sean ^a   Baregzay, Boran ^a   Spicer, Drew ^a   Singal, Pawan K ^b   Khaper, Neelam ^a  

^a LAKEHEAD UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Atherosclerosis; Diabetes; Dyslipidemia; Hypertension; Inflammation; Metabolic syndrome; Obesity; Oxidative stress

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL ADHESION MOLECULE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; RESISTIN; RETINOL BINDING PROTEIN 4; TETRAHYDROBIOPTERIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CARDIOVASCULAR DISEASE; CELL EXPANSION; CELL METABOLISM; CHRONIC INFLAMMATION; COMORBIDITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REDOX STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY CHAIN; REVIEW; SEDENTARY LIFESTYLE; VASCULAR SMOOTH MUSCLE; WAIST CIRCUMFERENCE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84873607705     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2012-0295     Document Type: Review

References (113)

1. Al-Aubaidy, H.A., and Jelinek, H.F. 2011. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur. J. Endocrinol. 164: 899-904. doi:10.1530/EJE-11-0053. PMID:21436346.
2. Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al., (International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity). 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. doi:10.1161/CIRCULATIONAHA. 109.192644. PMID:19805654.
3. Anrather, J., Racchumi, G., and Iadecola, C. 2006. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J. Biol. Chem. 281: 5657-5667. doi:10.1074/jbc.M506172200. PMID:16407283.
4. Apovian, C.M., Bigornia, S., Mott, M., Meyers, M.R., Ulloor, J., Gagua, M., et al. 2008. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol. 28: 1654-1659. doi:10.1161/ATVBAHA.108.170316. PMID: 18566296.
5. Arkan, M.C., Hevener, A.L., Greten, F.R., Maeda, S., Li, Z.-W., Long, J.M., et al. 2005. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11: 191-198. doi:10.1038/nm1185. PMID:15685170.
6. Barhoumi, T., Kasal, D.A., Li, M.W., Shbat, L., Laurant, P., Neves, M.F., et al. 2011. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension, 57: 469-476. doi:10.1161/HYPERTENSIONAHA. 110.162941. PMID:21263125.
7. Barker, B.R., Taxman, D.J., and Ting, J.P.-Y. 2011. Cross-regulation between the IL-1 /IL-18 processing inflammasome and other inflammatory cytokines. Curr. Opin. Immunol. 23: 591-597. doi:10.1016/j.coi.2011.07.005. PMID: 21839623.
8. Braun, N.A., Covarrubias, R., and Major, A.S. 2010. Natural killer T cells and atherosclerosis: form and function meet pathogenesis. J. Innate Immun. 2: 316-324. doi:10.1159/000296915. PMID:20375560.
9. Bremer, A.A., Mietus-Snyder, M., and Lustig, R.H. 2012. Toward a unifying hypothesis of metabolic syndrome. Pediatrics, 129: 557-570. doi:10.1542/peds. 2011-2912.
10. Briel, M., Ferreira-Gonzalez, I., You, J.J., Karanicolas, P.J., Akl, E.A., Wu, P., et al. 2009. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ, 338: b92. doi:10.1136/bmj.b92. PMID:19221140.
11. Brietzke, S.A. 2010. A personalized approach to metabolic aspects of obesity. Mt. Sinai. J. Med, 77: 499-510. doi:10.1002/msj.20206.
12. Brooks, G.C., Blaha, M.J., and Blumenthal, R.S. 2010. Relation of C-reactive protein to abdominal adiposity. Am. J. Cardiol. 106: 56-61. doi:10.1016/j.amjcard.2010.02.017. PMID:20609648.
13. Cangemi, R., Angelico, F., Loffredo, L., Del Ben, M., Pignatelli, P., Martini, A., and Violi, F. 2007. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radic. Biol. Med. 43: 853-859. doi:10.1016/j.freeradbiomed.2007.06.002. PMID:17664149.
14. Chaudhary, K., Buddineni, J.P., Nistala, R., and Whaley-Connell, A. 2011. Resistant hypertension in the high-risk metabolic patient. Curr. Diab. Rep. 11: 41-46. doi:10.1007/s11892-010-0155-x. PMID:20941645.
15. Cheng, X., Siow, R.C.M., and Mann, G.E. 2011. Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway. Antioxid. Redox Signal. 14: 469-487. doi:10.1089/ ars.2010.3283. PMID:20524845.
16. Corsetti, J.P., Gansevoort, R.T., Sparks, C.E., and Dullaart, R.P.F. 2010. Inflammation reduces HDL protection against primary cardiac risk. Eur. J. Clin. Invest. 40: 483-489. doi:10.1111/j.1365-2362.2010.02287.x. PMID:20412290.
17. Curtis, J.M., Grimsrud, P.A., Wright, W.S., Xu, X., Foncea, R.E., Graham, D.W., et al. 2010. Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction. Diabetes, 59: 1132-1142. doi:10.2337/db09-1105. PMID:20150287.
18. Davidsson, P., Hulthe, J., Fagerberg, B., and Camejo, G. 2010. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 30: 156-163. doi:10.1161/ATVBAHA.108. 179317. PMID:19778948.
19. De Miguel, C., Guo, C., Lund, H., Feng, D., and Mattson, D.L. 2011. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am. J. Physiol. Renal Physiol. 300: F734-F742. doi:10.1152/ajprenal.00454.2010. PMID:21159736.
20. Donath, M.Y., and Shoelson, S.E. 2011. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11: 98-107. doi:10.1038/nri2925. PMID:21233852.
21. Dorresteijn, J.A.N., Visseren, F.L.J., and Spiering, W. 2012. Mechanisms linking obesity to hypertension. Obes. Rev. 13: 17-26. doi:10.1111/j.1467-789X.2011. 00914.x. PMID:21831233.
22. Drummond, G.R., Selemidis, S., Griendling, K.K., and Sobey, C.G. 2011. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10: 453-471. doi:10.1038/nrd3403. PMID: 21629295.
23. Dworakowski, R., Alom-Ruiz, S.P., and Shah, A.M. 2008. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol. Rep. 60: 21-28. PMID:18276982.
24. Elbim, C., Guichard, C., Dang, P.M.C., Fay, M., Pedruzzi, E., Demur, H., et al. 2005. Interleukin-18 primes the oxidative burst of neutrophils in response to formyl-peptides: role of cytochrome b558 translocation and N-formyl peptide receptor endocytosis. Clin. Diagn. Lab. Immunol. 12: 436-446. doi:10.1128/ CDLI.12.3.436-446.2005. PMID:15753257.
25. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., et al. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114: 1752-1761. doi:10.1172/JCI21625. PMID: 15599400.
26. Gazi, I., Tsimihodimos, V., Filippatos, T., Bairaktari, E., Tselepis, A.D., and Elisaf, M. 2006. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metab. Clin. Exp. 55: 885-891. doi:10.1016/j.metabol.2006.02.015. PMID:16784959.
27. Goldin, A., Beckman, J.A., Schmidt, A.M., and Creager, M.A. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114: 597-605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID:16894049.
28. Goldstein, B.J., Mahadev, K., Wu, X., Zhu, L., and Motoshima, H. 2005. Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid. Redox Signal. 7: 1021-1031. doi:10.1089/ars.2005.7.1021. PMID: 15998257.
29. Gonzalez, C.D., Lee, M.-S., Marchetti, P., Pietropaolo, M., Towns, R., Vaccaro, M.I., et al. 2011. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy, 7: 2-11. doi:10.4161/auto.7.1.13044. PMID:20935516.
30. Henriksen, E.J., Diamond-Stanic, M.K., and Marchionne, E.M. 2011. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic. Biol. Med. 51: 993-999. doi:10.1016/j.freeradbiomed.2010.12.005. PMID: 21163347.
31. Hirooka, Y. 2011. Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertens. Res. 34: 407-412. doi:10.1038/hr.2011.14. PMID:21346766.
32. Hiukka, A., Maranghi, M., Matikainen, N., and Taskinen, M.-R. 2010. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev. Endocrinol. 6: 454-463. doi:10.1038/nrendo.2010.89. PMID:20567246.
33. Hoch, N.E., Guzik, T.J., Chen, W., Deans, T., Maalouf, S.A., Gratze, P., et al. 2009. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R208-R216. doi:10.1152/ajpregu. 90521.2008. PMID:19073907.
34. Hopps, E., and Caimi, G. 2012. Matrix metalloproteinases in metabolic syndrome. Eur. J. Intern. Med. 23: 99-104. doi:10.1016/j.ejim.2011.09.012. PMID:22284236.
35. Horváth, B., Mukhopadhyay, P., Haskó, G., and Pacher, P. 2012. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am. J. Pathol. 180: 432-442. doi:10.1016/j.ajpath.2011.11.003. PMID:22155112.
36. Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., et al. 2007. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes, 56: 901-911. doi:10.2337/db06-0911. PMID:17395738.
37. Hotamisligil, G.S. 1999. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes, 107: 119-125. doi:10.1055/s-0029-1212086. PMID:10320052.
38. Hulsmans, M., De Keyzer, D., and Holvoet, P. 2011. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J. 25: 2515-2527. doi:10.1096/fj.11-181149. PMID:21507901.
39. Ishigaki, Y., Katagiri, H., Gao, J., Yamada, T., Imai, J., Uno, K., et al. 2008. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation, 118: 75-83. doi:10.1161/CIRCULATIONAHA.107.745174. PMID: 18559699.
40. Kalkunte, S., Nevers, T., Norris, W.E., and Sharma, S. 2011. Vascular IL-10: a protective role in preeclampsia. J. Reprod. Immunol. 88: 165-169. doi:10.1016/j.jri.2011.01.009. PMID:21334073.
41. Kalupahana, N.S., and Moustaid-Moussa, N. 2012. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 13: 136-149. doi:10.1111/j.1467-789X.2011.00942.x. PMID:220334852.
42. Kassi, E., Pervanidou, P., Kaltsas, G., and Chrousos, G. 2011. Metabolic syndrome: definitions and controversies. BMC Med. 9: 48. doi:10.1186/1741-7015-9-48. PMID:21542944.
43. Kaul, N., Siveski-Iliskovic, N., Hill, M., Slezak, J., and Singal, P.K. 1993. Free radicals and the heart. J. Pharmacol. Toxicol. Methods, 30: 55-67. doi:10.1016/1056-8719(93)90008-3. PMID:8298182.
44. Kaur, K., Dhingra, S., Slezak, J., Sharma, A., Bajaj, A., and Singal, P. 2009. Biology of TNFalpha and IL-10, and their imbalance in heart failure. Heart Fail. Rev. 14: 113-123. doi:10.1007/s10741-008-9104-7. PMID:18712475.
45. Khan, T., Muise, E.S., Iyengar, P., Wang, Z.V., Chandalia, M., Abate, N., et al. 2009. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 29: 1575-1591. doi:10.1128/MCB.01300-08. PMID:19114551.
46. Khaper, N., Bryan, S., Dhingra, S., Singal, R., Bajaj, A., Pathak, C.M., and Singal, P.K. 2010. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid. Redox Signal. 13: 1033-1049. doi:10.1089/ars.2009.2930. PMID:20380580.
47. Kilhovd, B.K., Juutilainen, A., Lehto, S., Rönnemaa, T., Torjesen, P.A., Hanssen, K.F., and Laakso, M. 2007. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia, 50: 1409-1417. doi 10.1007/s00125-007-0687-z. 17479244.
48. Kintscher, U., Bramlage, P., Paar, W.D., Thoenes, M., and Unger, T. 2007. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6: 12. doi:10.1186/1475-2840-6-12. PMID:17407587.
49. Kohler, M., and Stradling, J.R. 2010. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 7: 677-685. doi:10.1038/nrcardio.2010.145.PMID:21079639.
50. Kotur-Stevuljevic, J., Memon, L., Stefanovic, A., Spasic, S., Spasojevic-Kalimanovska, V., Bogavac-Stanojevic, N., et al. 2007. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin. Biochem. 40: 181-187. doi:10.1016/j.clinbiochem.2006.09.007. PMID:17070511.
51. Kutuk, O., and Basaga, H. 2003. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol. Med. 9: 549-557. doi:10.1016/j.molmed.2003.10.007. PMID:14659470.
52. Lahoute, C., Herbin, O., Mallat, Z., and Tedgui, A. 2011. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat. Rev. Cardiol. 8: 348-358. doi:10.1038/nrcardio.2011.62. PMID:21502963.
53. Lassègue, B., and Griendling, K.K. 2010. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 30: 653-661. doi: 10.1161/ATVBAHA.108.181610. PMID:19910640.
54. Lastra, G., Habibi, J., Whaley-Connell, A.T., Manrique, C., Hayden, M.R., Rehmer, J., et al. 2009. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology, 150: 2561-2568. doi:10. 1210/en.2008-1391. PMID:19246535.
55. Lau, D.C.W., Douketis, J.D., Morrison, K.M., Hramiak, I.M., Sharma, A.M., Ur, E., The Obesity Canada Clinical Practice Guidelines Expert Panel. 2007. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. doi:10.1503/cmaj.061409. PMID: 17420481.
56. Leibowitz, A., and Schiffrin, E.L. 2011. Immune mechanisms in hypertension. Curr. Hypertens. Rep. 13: 465-472. doi:10.1007/s11906-011-0224-9. PMID:21842150.
57. Lim, S., Cho, Y.M., Park, K.S., and Lee, H.K. 2010. Persistent organic pollutants, mitochondrial dysfunction, and metabolic syndrome. Ann. N.Y. Acad. Sci. 1201: 166-176. doi:10.1111/j.1749-6632.2010.05622.x. PMID:20649553.
58. Lu, J., Mitra, S., Wang, X., Khaidakov, M., and Mehta, J.L. 2011. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid. Redox Signal. 15: 2301-2333. doi:10.1089/ars.2010.3792. PMID: 21338316.
59. Luo, P., Yan, M., Frohlich, E.D., Mehta, J.L., and Hu, C. 2011. Novel concepts in the genesis of hypertension: role of LOX-1. Cardiovasc. Drugs Ther. 25: 441-449. doi:10.1007/s10557-011-6337-1. PMID:21912849.
60. Maury, E., Ramsey, K.M., and Bass, J. 2010. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ. Res. 106: 447-462. doi:10.1161/CIRCRESAHA.109.208355. PMID:20167942.
61. Minamino, T., Orimo, M., Shimizu, I., Kunieda, T., Yokoyama, M., Ito, T., et al. 2009. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15: 1082-1087. doi:10.1038/nm.2014. PMID:19718037.
62. Moore, K.J., and Tabas, I. 2011. Macrophages in the pathogenesis of atherosclerosis. Cell, 145: 341-355. doi:10.1016/j.cell.2011.04.005.
63. Navab, M., Hama, S.Y., Anantharamaiah, G.M., Hassan, K., Hough, G.P., Watson, A.D., et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508. PMID:10974057
64. Navab, M., Reddy, S.T., Van Lenten, B.J., and Fogelman, A.M. 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232. doi:10.1038/nrcardio.2010.222. PMID:21304474.
65. Nian, M., Lee, P., Khaper, N., and Liu, P. 2004. Inflammatory cytokines and postmyocardial infarction modeling. Circ. Res. 94: 1543-1553. PMID: 15217919.
66. Nikolajczyk, B.S., Jagannathan-Bogdan, M., Shin, H., and Gyurko, R. 2011. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 12: 239-250. doi:10.1038/gene.2011.14. PMID:21390053.
67. Ordovas, J.M., Robertson, R., and Cléirigh, E.N. 2011. Gene-gene and geneenvironment interactions defining lipid-related traits. Curr. Opin. Lipidol. 22: 129-136. doi:10.1097/MOL.0b013e32834477a9. PMID:21311326.
68. Osborn, O., and Olefsky, J.M. 2012. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18: 363-374. doi: 10.1038/nm.2627. PMID:22395709.
69. Ouchi, N., Parker, J.L., Lugus, J.J., and Walsh, K. 2011. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11: 85-97. doi:10.1038/nri2921. PMID:21252989.
70. Page, S., Chandhoke, V., and Baranova, A. 2011. Melanin and melanogenesis in adipose tissue: possible mechanisms for abating oxidative stress and inflammation? Obes. Rev. 12: e21-e31. doi:10.1111/j.1467-789X.2010.00773.x. PMID: 20576005.
71. Paravicini, T.M., and Touyz, R.M. 2006. Redox signaling in hypertension. Cardiovasc. Res. 71: 247-258. doi:10.1016/j.cardiores.2006.05.001. PMID:16765337.
72. Peshavariya, H., Dusting, G.J., Di Bartolo, B., Rye, K.-A., Barter, P.J., and Jiang, F. 2009. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic. Res. 43: 772-782. doi:10.1080/10715760903045304. PMID:19521892.
73. Plantinga, Y., Ghiadoni, L., Magagna, A., Giannarelli, C., Franzoni, F., Taddei, S., and Salvetti, A. 2007. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am. J. Hypertens. 20: 392-397. doi:10.1016/j.amjhyper.2006.09.021. PMID: 17386345.
74. Power, M.L., and Schulkin, J. 2012. Maternal obesity, metabolic disease, and allostatic load. Physiol. Behav. 106: 22-28. doi:10.1016/j.physbeh.2011.09.011. PMID:21939681.
75. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., and Ridker, P.M. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286: 327-334. doi:10.1001/jama.286.3.327. PMID:11466099.
76. Putnam, K., Shoemaker, R., Yiannikouris, F., and Cassis, L.A. 2012. The reninangiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 302: H1219-30. doi:10.1152/ajpheart.00796.2011. PMID:22227126.
77. Rabkin, S.W. 2009. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat. Clin. Pract. Cardiovasc. Med. 6: 192-199. doi:10.1038/ncpcardio1453. PMID:19234499.
78. Reaven, G.M. 2011. The metabolic syndrome: time to get off the merry-go-round? J. Intern. Med. 269: 127-136. doi:10.1111/j.1365-2796.2010.02325.x. PMID:21129047.
79. Rinaudo, P., and Wang, E. 2012. Fetal programming and metabolic syndrome. Annu. Rev. Physiol. 74: 107-130. doi:10.1146/annurev-physiol-020911-153245.PMID:21910625.
80. Rizzo, M., Kotur-Stevuljevic, J., Berneis, K., Spinas, G., Rini, G.B., Jelic-Ivanovic, Z., et al. 2009. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res. 153: 217-223. doi:10.1016/j.trsl.2009.01.008. PMID: 19375682.
81. Rodrigo, R., González, J., and Paoletto, F. 2011. The role of oxidative stress in the pathophysiology of hypertension. Hypertens. Res. 34: 431-440. doi:10.1038/hr.2010.264. PMID:21228777.
82. Rye, K.-A., Bursill, C.A., Lambert, G., Tabet, F., and Barter, P.J. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50(Suppl.): S195-S200. doi:10.1194/jlr.R800034-JLR200. PMID:19033213.
83. Schmid-Schönbein, G.W. 2012. An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage. Curr. Hypertens. Rep. 14: 88-96. doi:10.1007/s11906-011-0240-9. PMID: 22081429.
84. Schulz, E., Gori, T., and Münzel, T. 2011. Oxidative stress and endothelial dysfunction in hypertension. Hypertens. Res. 34: 665-673. doi:10.1038/hr.2011.39. PMID:21512515.
85. Sharma, A.M. 2004. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension, 44: 12-19. doi:10.1161/01.HYP. 0000132568.71409.a2. PMID:15173127.
86. Shaw, J.E., Sicree, R.A., and Zimmet, P.Z. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87: 4-14. doi:10.1016/j.diabres.2009.10.007. PMID:19896746.
87. Shen, G.X. 2010. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can. J. Physiol. Pharmacol. 88: 241-248. doi:10.1139/Y10-018. PMID:20393589.
88. Sherman, C.B., Peterson, S.J., and Frishman, W.H. 2010. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev. 18: 141-147. doi:10.1097/CRD.0b013e3181c4b508. PMID:20395699.
89. Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116: 3015-3025. doi:10.1172/JCI28898. PMID:17053832.
90. Shields, M., Carroll, M.D., and Ogden, C.L. 2011. Adult obesity prevalence in Canada and the United States. NCHS Data Brief No. 56. Available from www.cdc.gov/nchs/data/databriefs/db56.pdf
91. Siasos, G., Tousoulis, D., Oikonomou, E., Zaromitidou, M., Stefanadis, C., and Papavassiliou, A.G. 2011. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr. Pharm. Des. 17: 4132-4146. doi: 10.2174/138161211798764780. PMID:22204374.
92. Singal, P.K., Khaper, N., Palace, V., and Kumar, D. 1998. The role of oxidative stress in the genesis of heart disease. Cardiovasc. Res. 40: 426-432. doi:10. 1016/S0008-6363(98)00244-2. PMID:10070480.
93. Stanhope, K.L. 2012. Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome. Annu. Rev. Med. 63: 329-343. doi:10.1146/annurev-med-042010-113026. PMID:22034869.
94. Stienstra, R., Joosten, L.A.B., Koenen, T., van Tits, B., van Diepen, J.A., van den Berg, S.A.A., et al. 2010. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12: 593-605. doi:10.1016/j.cmet.2010.11.011. PMID:21109192
95. Styskal, J., Van Remmen, H., Richardson, A., and Salmon, A.B. 2012. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic. Biol. Med. 52: 46-58. doi:10.1016/j. freeradbiomed.2011.10.441. PMID:22056908.
96. Sung, F.L., Zhu, T.Y., Au-Yeung, K.K.W., Siow, Y.L., and O, K. 2002. Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int. 62: 1160-1170. doi:10.1111/j.1523-1755. 2002.kid577.x. PMID:12234286.
97. Symonds, M.E., Sebert, S.P., Hyatt, M.A., and Budge, H. 2009. Nutritional programming of the metabolic syndrome. Nat Rev Endocrinol 5: 604-610. doi: 10.1038/nrendo.2009.195. PMID:19786987.
98. Tamashiro, K.L., Sakai, R.R., Shively, C.A., Karatsoreos, I.N., and Reagan, L.P. 2011. Chronic stress, metabolism, and metabolic syndrome. Stress, 14: 468-474. doi:10.3109/10253890.2011.606341. PMID:21848434
99. Tinsley, J.H., South, S., Chiasson, V.L., and Mitchell, B.M. 2010. Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure in hyper-tensive pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298: R713-R719. doi:10.1152/ajpregu.00712.2009. PMID:20053959.
100. Tocci, G., Paneni, F., Palano, F., Sciarretta, S., Ferrucci, A., Kurtz, T., et al. 2011. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am. J. Hypertens. 24: 582-590. doi:10.1038/ajh.2011.8. PMID:21331058.
101. Touyz, R.M., and Briones, A.M. 2011. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 34: 5-14. doi:10. 1038/hr.2010.201. PMID:20981034.
102. Undurti, A., Huang, Y., Lupica, J.A., Smith, J.D., DiDonato, J.A., and Hazen, S.L. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284: 30825-30835. doi:10.1074/jbc. M109.047605. PMID:19726691.
103. Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., et al. 2011. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care, 34: 1610-1616. doi:10.2337/dc11-0091.
104. Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., et al. 2011. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17: 179-188. doi:10.1038/nm. 2279. PMID:21217695.
105. Vasdev, S., Gill, V., and Singal, P. 2006. Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants. Exp. Clin. Cardiol. 11: 206-216. PMID:18651033.
106. Vlassara, H., and Striker, G.E. 2011. AGE restriction in diabetes mellitus: a paradigm shift. Nat. Rev. Endocrinol. 7: 526-539. doi:10.1038/nrendo.2011.74. PMID:21610689.
107. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808. doi:10.1172/JCI19246. PMID: 14679176.
108. Wen, H., Ting, J.P.-Y., and O'Neill, L.A.J. 2012. A role for the NLRP3 inflammasome in metabolic diseases - did Warburg miss inflammation? Nat. Immunol. 13: 352-357. doi:10.1038/ni.2228. PMID:22430788.
109. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830. doi:10.1172/JCI19451. PMID: 14679177.
110. Yan, S.F., Ramasamy, R., and Schmidt, A.M. 2010. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106: 842-853. doi:10.1161/CIRCRESAHA.109.212217. PMID:20299674.
111. Yan, M., Mehta, J.L., and Hu, C. 2011. LOX-1 and obesity. Cardiovasc Drugs Ther 25: 469-476. doi:10.1007/s10557-011-6335-3.
112. Yuan, Y., Jiao, X., Lau, W.B., Wang, Y., Christopher, T.A., Lopez, B.L., et al. 2010. Thioredoxin glycation: A novel posttranslational modification that inhibits its antioxidant and organ protective actions. Free Radic. Biol. Med. 49: 332-338. doi:10.1016/j.freeradbiomed.2010.04.017. PMID:20416371.
113. Zhao, Z., Zhao, C., Zhang, X.H., Zheng, F., Cai, W., Vlassara, H., and Ma, Z.A. 2009. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology, 150: 2569-2576. doi:10. 1210/en.2008-1342. PMID:19246537